Skip to Content

RxSight, Inc.

Securities Class Action

  • Date:
  • 9/22/2025
  • Company Name:
  • RxSight, Inc.
  • Stock Symbol:
  • RXST
  • Class Period:
  • FROM 11/7/2024 TO 7/8/2025
  • Status:
  • Filed
  • Filing Date:
  • 7/22/2025

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ:RXST) in the United States District Court for the Central District of California on behalf of all persons and entities who purchased or otherwise acquired RxSight securities between November 7, 2024 and July 8, 2025, both dates inclusive (the “Class Period”). Investors have until September 22, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The RxSight class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) RxSight was experiencing “adoption challenges” and/or structural issues resulting in declines in sales and utilization; (ii) defendants had overstated the demand for RxSight’s products; and (iii) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025.

The RxSight class action lawsuit further alleges that on July 8, 2025, RxSight reported preliminary second quarter of 2025 financial results, revealing significant declines in Light Delivery Device (“LDD”) sales, LAL utilization, and overall revenue. RxSight also lowered its full year 2025 guidance by approximately $42.5 million at the midpoint, and RxSight’s CEO, defendant Ronald Kurtz, disclosed that “[a]doption challenges over the last few quarters have been a primary reason for the LDD stall,” according to the complaint. The RxSight class action lawsuit alleges that on this news, the price of RxSight stock fell nearly 38%.
 
If you purchased or otherwise acquired RxSight shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or byfilling out the form below.  There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com with any questions regarding the case.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in RxSight. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: